Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Common Equity (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Common Equity for 11 consecutive years, with -$126.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 1755.92% to -$126.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$126.2 million, a 1755.92% decrease, with the full-year FY2025 number at -$126.2 million, down 1755.92% from a year prior.
  • Common Equity was -$126.2 million for Q4 2025 at Cartesian Therapeutics, down from -$35.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $93.8 million in Q4 2022 to a low of -$440.2 million in Q4 2023.
  • A 5-year average of -$17.3 million and a median of -$3.4 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 2222.36% in 2022, then tumbled 4866.49% in 2025.
  • Cartesian Therapeutics' Common Equity stood at $22.5 million in 2021, then surged by 316.62% to $93.8 million in 2022, then tumbled by 569.14% to -$440.2 million in 2023, then surged by 98.45% to -$6.8 million in 2024, then crashed by 1755.92% to -$126.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Common Equity are -$126.2 million (Q4 2025), -$35.8 million (Q3 2025), and -$2.5 million (Q2 2025).